Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Saline Shortages Persist, Providers Pin Hopes On Feds Demanding Backup Manufacturing Capacity

Executive Summary

As market forces, seasonal flu and extreme weather cause US shortages of intravenous saline solutions to persist, providers writing in NEJM are heartened by idea that federal Homeland Security Department could step in to require manufacturing redundancies. Will industry solve the problem before it becomes a matter of national security?

You may also be interested in...



How Will Pfizer Plant’s Tornado Damage Impact Congress’s Drug Shortages Debate?

The stakes on Capitol Hill rose another notch as tornado hit supplies of sterile injectable drugs at North Carolina plant. Workers escaped serious injury by gathering in designated shelters; patients may need effective legislation to escape serious injury from drug shortages.

The Quality Lowdown: As Washington Churns On Drug Shortages, Supply Chain Challenges Grow

While FDA commissioner meets with firms on shortages, senators challenge alternative source of platinum chemotherapies, FDA hinges imports from Sun plant on successful media fill runs, Safe Chain warned on Biktarvy suppliers, and the FDA asks Ipca more questions while setting “Mr. Ye” straight.

BARDA Lays Out Vision For Next Pandemic: Vaccines For The US Within 130 Days

Federal agency seeks dialogue with industry on how to enable surge capacity for pandemic vaccines without cutting back on other production.One key factor: workforce development.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel